Zoryve® (roflumilast) – New formulation approval
December 15, 2023 - Arcutis Biotherapeutics announced the FDA approval of Zoryve (roflumilast), for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
Download PDF
